Добавил:
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

книга / 2016_Kaplan_USMLE_Step_1_Lecture_Notes_Pharmacology

.pdf
Скачиваний:
486
Добавлен:
10.03.2021
Размер:
5.9 Mб
Скачать

Steroid Hormones

2

Learning Objectives

Describe clinical situations requiring the use of adrenal steroids, estrogens, and progestin

Solve problems concerning oral contraceptives

List the common complications of steroid hormone use

ADRENAL STEROIDS

λNonendocrine uses: For use in inflammatory disorders (and accompanying adverse effects), see Section VI, Drugs for Inflammatory and Related Disorders.

λEndocrine uses of glucocorticoids (e.g., prednisone, dexamethasone, hydrocortisone) and the mineralocorticoid (fludrocortisone) include:

Addison disease replacement therapy

Adrenal insufficiency states (infection, shock, trauma) supplementation

Premature delivery to prevent respiratory distress syndrome supplementation

Adrenal hyperplasia feedback inhibition of ACTH

λAdrenal steroid antagonists:

Spironolactone

Blocks aldosterone and androgen receptors (see Section III, Cardiac and Renal Pharmacology)

λMifepristone:

Blocks glucocorticoid and progestin receptors

λSynthesis inhibitors:

Metyrapone (blocks 11-hydroxylation)

Ketoconazole

ESTROGENS

λPharmacology: Estradiol is the major natural estrogen. Rationale for synthetics is to oral bioavailability, half-life, and feedback inhibition of FSH and LH.

λDrugs:

Conjugated equine estrogens (Premarin)—natural

Ethinyl estradiol and mestranol—steroidal

279

Section VIII λ Endocrine Pharmacology

λClinical uses:

Female hypogonadism

Hormone replacement therapy (HRT) in menopause →↓ bone resorption (PTH)

Contraception—feedback of gonadotropins

Dysmenorrhea

Uterine bleeding

Acne

Prostate cancer (palliative)

λSide effects:

General

ºNausea

ºBreast tenderness

ºEndometrial hyperplasia

ºgallbladder disease, cholestasis

ºMigraine

ºBloating

blood coagulation via antithrombin III and factors II, VII, IX, and X (only at high dose)

Cancer risk

ºendometrial cancer (unless progestins are added)

ºbreast cancer—questionable, but caution if other risk factors are present

ºDES given during breast feeding →↑ vaginal adenocarcinoma cancer in offspring

λOther drugs:

Anastrozole

ºMode of action: aromatase inhibitor →↓ estrogen synthesis

ºUse: estrogen-dependent, postmenopausal breast cancer

 

 

Aromatase

 

 

 

 

 

Androstenedione

 

Estrone

 

 

Estradiol

 

 

 

 

 

 

 

(adrenal cortex)

 

 

 

(adipose)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Anastrozole

Figure VIII-2-1. Mechanism of Action of Anastrozole

Clomiphene (fertility pill)

ºMode of action: feedback inhibition →↑ FSH and LH →↑ ovulation pregnancy

ºUse: fertility drug

ºAdverse effect: multiple births

280

Chapter 2 λ Steroid Hormones

λSelective estrogen-receptor modulators (SERMs):

Tamoxifen

ºVariable actions depending on “target” tissue

ºE-receptor agonist (bone), antagonist (breast), and partial agonist (endometrium)

ºPossible risk of endometrial cancer

ºUsed in estrogen-dependent breast cancer and for prophylaxis in highrisk patients

Raloxifene

ºE-receptor agonist (bone), antagonist breast and uterus

ºWhen used in menopause, there is no cancer risk

ºUse: prophylaxis of postmenopausal osteoporosis, breast cancer

Table VIII-2-1. Comparison of Tamoxifen and Raloxifene in Various Tissues

Drug

 

Bone

 

Breast

 

Endometrium

Tamoxifen

Agonist

Antagonist

Agonist

Raloxifene

Agonist

Antagonist

Antagonist

PROGESTIN

λPharmacology: Progesterone is the major natural progestin. Rationale for synthetics is oral bioavailability and feedback inhibition of gonadotropins, especially luteinizing hormone (LH).

λDrugs:

Medroxyprogesterone

Norethindrone

Desogestrel is a synthetic progestin devoid of androgenic and antiestrogenic activities, common to other derivatives

λClinical uses:

Contraception (oral with estrogens)—depot contraception (medroxyprogesterone IM every 3 months)

Hormone replacement therapy (HRT)—with estrogens to endometrial cancer

λSide effects:

HDL and LDL

Glucose intolerance

Breakthrough bleeding

Androgenic (hirsutism and acne)

Antiestrogenic (block lipid changes)

Weight gain

Depression

λAntagonist: mifepristone—abortifacient (use with prostaglandins [PGs])

281

Section VIII λ Endocrine Pharmacology

ORAL CONTRACEPTIVES

λPharmacology:

Combinations of estrogens (ethinyl estradiol, mestranol) with progestins (norgestrel, norethindrone) in varied dose, with mono-, bi-, and triphasic variants

Suppress gonadotropins, especially midcycle LH surge

λSide effects:

Side effects are those of estrogens and progestins, as seen previously

λInteractions: contraceptive effectiveness when used with antimicrobials and enzyme inducers

λBenefits:

risk of endometrial and ovarian cancer

dysmenorrhea

endometriosis

pelvic inflammatory disease (PID)

osteoporosis

ANDROGENS

λPharmacology: include methyltestosterone and 17-alkyl derivatives with increased anabolic actions, e.g., oxandrolone, nandrolone

λUses:

Male hypogonadism and for anabolic actions →↑ muscle mass, RBCs, nitrogen excretion

Illicit use in athletics

λSide effects:

Excessive masculinization

Premature closure of epiphysis

Cholestatic jaundice

Aggression

Dependence

λAntagonists:

Flutamide: androgen receptor blocker—used for androgen-receptor– positive prostate cancer

Leuprolide: GnRH analog—repository form used for androgen-receptor– positive prostate cancer

Finasteride

º5-Alpha reductase inhibitor, preventing conversion of testosterone to dihydrotestosterone (DHT)

ºDHT is responsible for hair loss and prostate enlargement

ºUses: BPH, male pattern baldness

ºCaution: teratogenicity

282

Chapter 2 λ Steroid Hormones

 

5α-Reductase

 

 

 

 

 

Hair loss

 

 

 

 

 

Testosterone

 

DHT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Prostate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

growth

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Finasteride

Figure VIII-2-2. Mechanism of Action of Finasteride

Chapter Summary

Adrenal Steroids

λThe nonendocrine uses in inflammatory disorders were discussed in the previous chapter.

λThe glucocorticoids are used to treat Addison disease and adrenal insufficiency states, as a supplement in infantile respiratory distress syndrome, and in adrenal hyperplasia.

Estrogens

λSynthetic estrogens are used to increase the oral bioavailability and half-life relative to that obtained with estradiol and to induce feedback inhibition of FSH and LH.

λThe uses and adverse affects of estrogens are listed.

λThe clinical uses of anastrozole (decreases estrogen synthesis), danazol (decreases ovarian steroid synthesis), clomiphene (decreases feedback inhibition), and the selective estrogen-receptor modulators tamoxifen and raloxifene are considered.

Progestin

λSynthetic progestins are used to increase oral bioavailability and half-life relative to progesterone and to induce feedback inhibition of gonadotropins, especially LH.

λThe progestin-like drugs, their use in contraception and in hormonal replacement therapy, and their adverse effects are considered.

λMifepristone is an antagonist used with PG as an abortifacient.

λThe pharmacology of oral contraceptives and their adverse effects, drug interactions, and benefits are pointed out.

Androgens

λClinically useful androgen analogs include methyltestosterone and 17-alkyl derivatives. Their clinical and illicit uses and side effects are presented.

λClinically useful drug antagonists are flutamide (an androgen-receptor blocker used to treat prostate cancer), leuprolide (a GnRH analog used to treat prostate cancer), and finasteride (a 5-α-reductase inhibitor used to treat benign prostatic hyperplasia and male pattern baldness).

283

Antithyroid Agents

3

Learning Objectives

Describe the short-term effect of iodine on the thyroid and the most commonly used thioamides

Table VIII-3-1. The Synthesis of Thyroid Hormone and Action and Effects of Antithyroid Agents

Thyroid Hormone Synthesis

 

Effects of Antithyroid Agents

1. Active accumulation of iodide into gland

 

Basis for selective cell destruction by 131I

2.

Oxidation of iodide to iodine by peroxidase

 

Inhibited by thioamides

3.

Iodination of tyrosyl residues (organification) on thyroglobulin to

 

Inhibited by thioamides

 

form MIT and DIT

 

 

4.

Coupling of MIT and DIT to form T3 and T4

 

Inhibited by thioamides

5.

Proteolytic release of T3 and T4 from thyroglobulin

 

Inhibited by high doses of iodide*

6. Conversion of T4 to T3 via 5´ deiodinase in peripheral tissues

 

Inhibited by propranolol* and propylthiouracil*

Definition of abbreviations: MIT, monoiodotyrosine; DIT, diiodotyrosine; T3, triiodothyronine; T4, thyroxine. *Thyroid storm management may include the use of any or all of these agents.

Iodide

2

 

Iodine

3 MIT

4

T3

T4 - TG

 

 

 

DIT

 

Thyroid

 

 

 

 

 

peroxidase

 

 

 

 

 

 

TG

 

1

5

TG

 

 

Iodide

T3 T4

6 T3

Figure VIII-3-1. Thyroid Hormone Synthesis

285

Section VIII λ Endocrine Pharmacology

λThioamides: propylthiouracil and methimazole

Use: uncomplicated hyperthyroid conditions; slow in onset

High-dose propylthiouracil inhibits 5deiodinase

Common maculopapular rash

Both drugs cross the placental barrier, but propylthiouracil is safer in pregnancy because it is extensively protein bound

λIodide

Potassium iodide plus iodine (Lugol’s solution) possible use in thyrotoxicosis: used preoperatively →↓ gland size, fragility, and vascularity

No long-term use because thyroid gland “escapes” from effects after 10 to 14 days

λI131: most commonly used drug for hyperthyroidism

Chapter Summary

λThe steps in thyroid hormone synthesis and the antithyroid agents’ effects upon them are summarized in Table VIII-3-1. The clinical uses and their potential complications are presented in greater detail for the thioamides (propylthiouracil and methimazole) and iodine.

286

Drugs Related to Hypothalamic

4

and Pituitary Hormones

Learning Objectives

List commonly used pharmacologic agents that directly affect hypothalamic and pituitary hormone release

Table VIII-4-1. Drugs Related to Hypothalamic and Pituitary Hormones

Hormone

 

Pharmacologic Agent

 

Clinical Uses

GH

 

Somatrem or somatropin

 

Pituitary dwarfism, osteoporosis

Somatostatin

 

Octreotide

 

Acromegaly, carcinoid and

 

 

 

 

secretory-GI tumors

ACTH

 

Cosyntropin

 

Infantile spasms

GnRH

 

Leuprolide, nafarelin

 

Endometriosis, prostate carcinoma

 

 

 

 

(repository form)

FSH and LH

 

Urofollitropin (FSH),

 

Hypogonadal states

 

 

placental HCG (LH),

 

 

 

 

menotropins (FSH and LH)

 

 

PIH (DA)

 

Cabergoline

 

Hyperprolactinemia

Oxytocin

 

Oxytocin

 

Labor induction

Vasopressin

 

Desmopressin

 

λ Neurogenic (pituitary) diabetes

 

 

(V2 selective)

 

insipidus

 

 

 

 

λ Hemophilia A (↑ factor VIII from

 

 

 

 

liver)

 

 

 

 

λ von Willebrand disease (↑ vW

 

 

 

 

factor from endothelium)

 

 

 

 

λ Primary nocturnal enuresis

Definition of abbreviations: ACTH, adrenocorticotropin hormone; DA, dopamine; FSH, follicle-stim- ulating hormone; GH, growth hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; PIH, prolactin-inhibiting hormone.

Chapter Summary

λThe clinical uses of drugs used to treat functions associated with hypothalamic or pituitary hormones are summarized in Table VIII-4-1.

Clinical Correlate

Drugs useful in the syndrome of inappropriate secretion of ADH (SIADH) include demeclocycline and tolvaptan, which block V2 receptors in the collecting duct. Loop diuretics, salt tablets, and fluid restriction are also useful strategies.

287